Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness.

Eckman DM, Stacey RB, Rowe R, D'Agostino R Jr, Kock ND, Sane DC, Torti FM, Yeboah J, Workman S, Lane KS, Hundley WG.

PLoS One. 2013;8(2):e57554. doi: 10.1371/journal.pone.0057554. Epub 2013 Feb 21.

2.

Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.

Hydock DS, Lien CY, Jensen BT, Parry TL, Schneider CM, Hayward R.

Exp Biol Med (Maywood). 2012 Dec;237(12):1483-92. doi: 10.1258/ebm.2012.012137.

PMID:
23354407
3.

Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats.

Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ.

Tumori. 2010 May-Jun;96(3):460-4.

4.

Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding.

Hydock DS, Lien CY, Jensen BT, Schneider CM, Hayward R.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1551-60. doi: 10.1007/s00280-013-2154-5. Epub 2013 Apr 9.

PMID:
23568281
5.

Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Jordan J, Workman S, Hundley WG.

Circ Cardiovasc Imaging. 2010 Sep;3(5):550-8. doi: 10.1161/CIRCIMAGING.109.918540. Epub 2010 Jul 9.

6.

Effect of Shengmai injection () on diaphragmatic contractility in doxorubicin-treated rats.

Ge M, Fang YY, Liu GP, Guan SD.

Chin J Integr Med. 2014 Jan;20(1):43-8. doi: 10.1007/s11655-012-1096-9. Epub 2012 Aug 18.

PMID:
22903440
7.

Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.

Mohamed HE, Asker ME, Ali SI, el-Fattah TM.

J Pharm Pharmacol. 2004 Jun;56(6):757-68.

PMID:
15231041
8.

Exercise mitigates cardiac doxorubicin accumulation and preserves function in the rat.

Jensen BT, Lien CY, Hydock DS, Schneider CM, Hayward R.

J Cardiovasc Pharmacol. 2013 Sep;62(3):263-9. doi: 10.1097/FJC.0b013e3182982ce0.

PMID:
23644988
9.

Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.

Segredo MP, Salvadori DM, Rocha NS, Moretto FC, Correa CR, Camargo EA, de Almeida DC, Reis RA, Freire CM, Braz MG, Tang G, Matsubara LS, Matsubara BB, Yeum KJ, Ferreira AL.

Hum Exp Toxicol. 2014 Jul;33(7):748-60. doi: 10.1177/0960327113512342. Epub 2013 Nov 25.

PMID:
24275640
10.

Physical exercise prior and during treatment reduces sub-chronic doxorubicin-induced mitochondrial toxicity and oxidative stress.

Marques-Aleixo I, Santos-Alves E, Mariani D, Rizo-Roca D, Padrão AI, Rocha-Rodrigues S, Viscor G, Torrella JR, Ferreira R, Oliveira PJ, Magalhães J, Ascensão A.

Mitochondrion. 2015 Jan;20:22-33. doi: 10.1016/j.mito.2014.10.008. Epub 2014 Nov 7.

PMID:
25446396
11.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

PMID:
18695136
12.

Endurance exercise attenuates cardiotoxicity induced by androgen deprivation and doxorubicin.

Parry TL, Hydock DS, Jensen BT, Lien CY, Schneider CM, Hayward R.

Can J Physiol Pharmacol. 2014 May;92(5):356-62. doi: 10.1139/cjpp-2013-0294. Epub 2014 Mar 10.

PMID:
24784469
13.

Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.

Saad SY, Najjar TA, Alashari M.

J Biochem Mol Toxicol. 2004;18(2):78-86.

PMID:
15122649
14.

Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).

Chakrabarti KB, Hopewell JW, Wilding D, Plowman PN.

Eur J Cancer. 2001 Jul;37(11):1435-42.

PMID:
11435077
15.

Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure.

Törnig J, Gross ML, Simonaviciene A, Mall G, Ritz E, Amann K.

J Am Soc Nephrol. 1999 Jan;10(1):77-83.

16.

Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.

Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T.

Life Sci. 1999;65(12):1265-74.

PMID:
10503942
17.

The influence of a thyroxine supplemented diet on selected hepatic redox equilibrium markers, liver morphology and the serum lipid profile in rats treated with doxorubicin.

Korga A, Dudka J, Burdan F, Wronecki L, Sierocinska-Sawa J, Iwan M, Korobowicz-Markiewicz A, Korobowicz E.

Postepy Hig Med Dosw (Online). 2013 Mar 5;67:143-9.

18.

[Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].

Elbl L, Vásová I, Krejcí M, Navrátil M, Tomásková I, Jedlicka F, Chaloupka V, Mayer J, Vorlícek J.

Vnitr Lek. 2006 Mar;52(3):221-31. Czech.

PMID:
16722153
19.

Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity.

Chen X, Guo Z, Wang P, Xu M.

Heart Lung Circ. 2014 Aug;23(8):772-7. doi: 10.1016/j.hlc.2014.02.015. Epub 2014 Mar 12.

PMID:
24685074
20.

Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.

Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G, George J.

Eur Heart J. 2006 Aug;27(15):1876-83. Epub 2006 May 26.

PMID:
16731534

Supplemental Content

Support Center